Global automated hematology analyzer Market - 2024-2031

Global automated hematology analyzer Market - 2024-2031

The global automated hematology analyzer market reached US$ 456 million in 2023 and is expected to reach US$ 795 million by 2031, growing with a CAGR of 7.2% during the forecast period 2024-2031.

Automated hematology analyzers are computerized, highly specialized machines that count the number of different types of red and white blood cells, blood platelets, hemoglobin, and hematocrit levels in a blood sample.

They include programmable automated alarm systems for indicating results outside the reference range. Hematology analyzers are concerned with the detection, and monitoring of diseases, prognosis, and subsequent screening and are extensively used against various blood-related diseases such as hemophilia, blood cancer, and blood clots. Other diseases include leukemia, anemia, blood transfusion, malignant lymphomas, and others where hematology diagnosis is used.

The market is driven by factors such as the rise in the prevalence of blood disorders, increasing technological advancements, and rising adoption rates of automated hematology instruments.

Market Dynamics: Drivers

Rise in Prevalence of Blood Disorders

The demand for the global automated hematology analyzer market is driven by multiple factors. One of the primary factors is the increase in the incidence of blood disorders driving the market growth. The Department of Health and Aged Care of the Australian Government reported in December 2022 that there were about 330,000 affected babies born every year, 83% of whom had disorders of sickle cell, 17% had thalassemia, 7% of expectant mothers had hemoglobin disorders, and more than 1% of the couples worldwide were at risk.

According to a World Federation of Hemophilia research study published in October 2023, there were a higher number of 830,895 males worldwide having hemophilia, and about 2,82,266 of these have a severe type of condition that is the most underdiagnosed. Early diagnosis, as well as treatment, are some of the most effective ways to maintain a patient's quality of life when they have a blood cell problem.

Moreover, key players in the industry more focus on the technological advantages of the hematology analyzer would drive this market growth. For instance, in July 2022, Sysmex Corporation announced the launch of new sample transportation system modules that can be connected to the XR-Series Automated Hematology Analyzer (XR-Series), its flagship model in the hematology field.

Also, in March 2022, Mindray launched the new BC-700 Series, a revolutionary hematology analyzer series that incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests. This series, including two open vial models BC-700/BC-720 and two autoloader models BC-760/BC-780, is designed to empower medium-volume laboratories with advanced diagnostics technologies that are applied in the premium products.

Restraints

Factors such as the high cost of the analyzer, time-consuming & stringent regulatory requirements, limited availability of skilled technicians, and limited reimbursement policies are expected to hamper the market.

Segment Analysis

The global automated hematology analyzer market is segmented based on product & service, type, application, and end-user.

The 3-part hematology analyzer segment accounted for approximately 65.4% of the global automated hematology analyzer market share

The 3-part hematology analyzer segment is expected to hold the largest market share over the forecast period. The 3-part hematology analyzer measures the volume of white blood cells electrically & categorizes blood cells, based on their size, divides into three groups: a small white blood cell group (lymphocytes), a medium-sized white blood cell group (monocytes, eosinophils, and basophils), & large white blood cell group. This test can be used to detect a variety of conditions, such as anemia, infection, and leukemia.

Moreover, key players in the market product launches and introducing innovative technological advancements in the hematology analyzers would drive this segment's growth. For instance, in March 2024, Agappe will launch the most advanced hematology analyzers. AG Innovate will be a customer engagement program where the customers can experience the unveiling of a revolutionary automated 3rd generation hematology analyzer and AE-powered CLIA analyzer.

Similarly, at Medlab Middle East in February 2024, Dymind is also showcasing the DH20 3-part auto hematology analyzer. Compact and user-friendly, the DH20 can measure more clinical parameters using only 9ul sample volume and comes with an optional RF card and barcode function.

Also, in April 2022, Sysmex Europe has recently launched its new three-part differential system ‘XQ-320 XQ-Series Automated Hematology Analyzer’, answering the needs of this important high-volume market segment. XQ-320 brings excellence in quality to a diverse range of clinical laboratory environments with reliable technology and a new level of usability.

Geographical Analysis

North America accounted for approximately 43.2% of the global automated hematology analyzer market share

North American region is expected to hold the largest market share over the forecast period owing to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the major players in this region helps to drive this market growth.

Blood Cancers are one of the driving factors in this region. According to the Leukemia and Lymphoma Society, in 2023, approximately every 3 minutes, one person in the U.S. is diagnosed with leukemia, lymphoma, or myeloma. An estimated combined total of 184,720 people in the U.S. are expected to be diagnosed with leukemia, lymphoma, or myeloma.

Moreover, key players in the industry introducing new product launches and approvals help to drive this market growth. For instance, in August 2023, Abbott received U.S. Food and Drug Administration clearance for its advanced Alinity h-series hematology system, paving the way for laboratories throughout the country to run complete blood counts (CBC) as a part of Abbott’s Alinity family of diagnostic products.

Also, in January 2024, HORIBA Medical launched the new HELO 2.0 high throughput automated hematology platform which is CE-IVDR approved, with pending US FDA approval. Following the success of HORIBA Medical’s previous HELO, this new generation high-end hematology range has been designed in consultation with customers to further improve and cover all needs of high throughput fully automated hematology.

Market Segmentation

By Product & Service
• Instruments
3 Part Hematology Analyzer
5 Part Hematology Analyzer
Point-of-care Testing Hematology Analyzers
Others
• Reagents & Consumables
• Services

By Type
• Fully-Automated Hematology Analyzers
• Semi-automated Hematology Analyzers

By Application
• Hemorrhagic Conditions
• Blood Cancer
• Anaemia
• Infections
• Immune Disorders
• Others

By End-user
• Hospitals
• Clinical Laboratories
• Academic and Research Institutes
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the automated hematology analyzer market include Beckman Coulter, Inc., Accurex, Everlife CPC Diagnostics, Sysmex, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Abbott, Horiba Medical, Biobase Biodusty(Shandong), Co., Ltd, Siemens Healthineers and F. Hoffmann-La Roche Ltd among others.

Key Developments

In June 2024, Horiba expanded its line of compact hematology instruments by introducing new models that integrate Erythrocyte Sedimentation Rate (ESR) testing, enhancing diagnostic capabilities with rapid results and comprehensive disease profiling.

In February 2024, Dymind Biotechnology (Shenzhen, China) is introducing its breakthroughs in medical solutions for hematology, coagulation, POCT, immunology, and veterinary at Medlab Middle East 2024, including its new high-end hematology analyzer DH-800 with innovative functions.

In May 2023, Siemens Healthineers launched next-gen hematology analyzers, workflow barriers removed to help patients get results faster. The Atellica HEMA 570 Analyzer and the Atellica HEMA 580 Analyzer. Vital to patient care, the complete blood count (CBC) is among the most performed diagnostic tests in the lab and often provides the first indication of illness in a patient.

Why Purchase the Report?
• To visualize the global automated hematology analyzer market segmentation based on product & service, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of automated hematology analyzer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available in Excel consisting of key products of all the major players.

The global automated hematology analyzer report would provide approximately 70 tables, 69 figures, and 182 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies